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Background: Acetaminophen administration for more than 4 days causes aminotransferase elevation in some
subjects. The objective of this randomized, placebo-controlled trial is to describe the course of alanine
aminotransferase (ALT) elevation in subjects administered 4 g/day of acetaminophen for at least 16 days.
Methods: A randomized, placebo controlled trial of acetaminophen (4 g/day) vs placebo. Subjects were healthy
volunteers with normal liver enzymes. The primary outcome was the course of ALT during acetaminophen
administration. All subjects were treated for a minimum of 16 days. Subjects with ALT elevation at day 16 were
continued on treatment until these elevations resolved up to a maximum of 40 days. Subjects were also evaluated
for elevation of INR or serum bilirubin as evidence of hepatic dysfunction.
Results: 157/205 (77%) completed acetaminophen subjects had no ALT elevation or transient elevations that
resolved by day 16. Of the 48 subjects who had ALT elevations at study day 16, 47 continued on acetaminophen
and had resolution by study day 40. One acetaminophen subject did not have resolution by study day 40, and the
course of aminotransferase elevation suggests an alternative cause. One placebo subject had an ALT elevation at
day 16 that resolved by day 22. The highest observed ALT among all acetaminophen subjects was 191 IU/L. The
mean ALT at day 16 was 4.4 IU/L higher for the acetaminophen than for the placebo group. No subject developed
liver dysfunction.
Conclusions: A minority of subjects treated with 4 g/day of acetaminophen for 16 days will have low-grade
aminotransferase elevations that are not accompanied by liver dysfunction and resolve if administration is continued.
Trials registration: Clintrials.gov NCT00743093 registered August 26, 2008
Keywords: Alanine aminotransferase, Drug-induced liver injury, HepatotoxicityBackground
Acetaminophen (paracetamol) is a commonly used an-
algesic and antipyretic that has an excellent safety profile
when taken in doses of 4 g/day or less [1]. However,
several studies have found that a significant percentage
of subjects who ingest 2–4 g of acetaminophen per day
for more than 4 consecutive days develop asymptomatic* Correspondence: Kennon.Heard@rmpdc.org
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[2-6]. These studies generally stopped dosing before the
ALT elevations resolved. Multiple clinical studies have not
identified any cases of liver failure with long-term acet-
aminophen use [7-11]. In contrast to prospective studies
that found no cases of liver failure, there are anecdotal re-
ports of patients who develop liver failure while allegedly
taking therapeutic doses [12]. Given the widespread use of
acetaminophen, if asymptomatic elevations of aminotrans-
ferase activity with therapeutic doses can progress to liver
failure, even rarely, there is a substantial risk to public
health.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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when acetaminophen is administered longer than 4
consecutive days is not well characterized. Anecdotally,
patients take acetaminophen for years (as single ingredient
and in combination with opioids) without symptomatic
liver injury. In a small, placebo controlled 4-week study
measuring the effect of acetaminophen on warfarin-
induced anticoagulation, Parra reported a dose-dependent
elevation in mean serum aminotransferase activity in
subjects at two weeks during treatment with 2 or 4 g/day of
acetaminophen [5]. Unlike other studies, acetaminophen
was continued despite the mild increases in aminotrans-
ferase activity. These elevations resolved by week 4 of
treatment and no subject had evidence of liver dysfunction.
However, this study only included 15 acetaminophen-
treated subjects and serum aminotransferase activity was
only measured at baseline, 2 and 4 weeks. While this study
suggests that the aminotransferase elevations resolve if
therapy is continued, the course is not fully characterized.
The objective of this study is to describe the changes
in serum aminotransferase activity in healthy subjects
taking 4 g/day of acetaminophen for a minimum of 16 days
and continued until any observed ALT elevations resolve.
Our secondary aims were to determine if subjects who
had aminotransferase elevations developed liver dys-
function and finally to determine if subjects who develop




This was a randomized, placebo controlled trial. Subjects
were randomized 4:1 acetaminophen to placebo. This
randomization plan was intended to increase the power
of the study to detect infrequent adverse events in the
acetaminophen group. This study was registered with
clinicaltrials.gov (NCT00743093) and approved by The
Colorado Multiple Institutional Review Board.
Participants
This was an outpatient study; subjects were evaluated at
one of two clinical research sites. Subjects were recruited
from a research listserv, posters, classified advertisement
website (Craigslist) postings and media advertising. All
subjects provided informed consent.
We included male and female subjects who were age
18 years or older and who did not have any of the follow-
ing exclusion criteria: History of acetaminophen ingestion
on any of the four days preceding study enrollment or a
measurable serum acetaminophen concentration at time
of enrollment; laboratory testing suggesting active viral
hepatitis A,B or C infection; any of the following tests
greater than the upper limit of normal at screening:
serum aminotransferase or total bilirubin, InternationalNormalized Ratio (INR) or alkaline phosphatase activity;
platelet count less than 125,000/mL; positive pregnancy
test; history of cholelithiasis (without cholecystectomy);
history of heavy ethanol use defined as consuming more
than an average of 3 alcohol containing drinks daily or 3
or more alcohol containing drinks on any given day over
the preceding 2 weeks prior to study enrollment [13];
new prescription medication started within the previous
30 days; taking isoniazid or warfarin; currently has an-
orexia nervosa or reports a fasting type diet; clinically
intoxicated, psychiatrically impaired or unable to give
informed consent for any reason; known hypersensitivity
or allergy to acetaminophen.
Interventions
Subjects were administered acetaminophen 4 g/day or
placebo. Subjects were instructed to take 2 × 500 mg
tablets every 4 hours for 4 doses each day (the exact tim-
ing varied but subjects were asked to take the doses
every 4 hours after the first dose each day). The subjects
noted the time of ingestion for each dose in a study
diary. They also recorded other medications and alcohol
consumption. Compliance was verified by study diary
and pill counts at each study visit.
We included a placebo group for two reasons. First we
recognized that there is day-to-day variation in amino-
transferase activity and we felt it was important to be able
to account for this variation as we quantified the effect of
acetaminophen. Second, we have planned secondary stud-
ies to identify potential characteristics and biomarkers that
may suggest a mechanism for these elevations.
The following tests were performed at each visit: serum
aminotransferase (alanine aminotransferase-ALT and as-
partate aminotransferase-AST), total bilirubin (TBL) and
International Normalized Ratio (INR). Additional testing
at the screening visit (study day −7 to −1) included a
complete blood count, hepatitis A and C antibodies,
hepatitis B antigen, serum acetaminophen and serum
pregnancy (females only). Serum acetaminophen con-
centrations were also measured at day 10 and 16 for
safety purposes but were not reported to study personnel
unless they were above the critical concentration for our
laboratory (>40 mcg/mL or 264 micromol/L) to maintain
blinding. Adverse events were recorded using a structured
interview at each visit. Subjects were specifically asked if
they had nausea, vomiting, abdominal pain or jaundice
and asked if they had any other symptoms.
Patients were evaluated (including laboratory testing
as described above) on study days 0 (baseline), 4, 7, 10, 13
and 16. At day 16, subjects were assessed for resolution
(as defined in the outcome section below). Subjects who
did not meet resolution criteria by day 16 went into the
extended dosing period. In the extended study period,
subjects continued treatment as assigned and continued
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ject did not have resolution by study day 40, the study
drug administration was stopped and the subject was
monitored every 3 days until day 49. If the subject did not
have resolution by that point, they were referred to a hepa-
tologist for further evaluation and monitoring (Figure 1).
Outcomes
As ALT is considered a more specific biomarker for the
liver than AST, the primary outcome of this study was
resolution of ALT elevation. Resolution criteria were
defined at day 16 as an ALT that was less than 47 IU/L
(the upper limit of the reference range for our laboratory)
and within 10 IU/L of the subject’s baseline value. Subjects
who did not meet resolution criteria were continued on
the study protocol.
The resolution criteria after day 16 were dependent on
the day 16 ALT values.
If the subject had a day 16 ALT >47 IU/L, we required 2
consecutive ALT values less than or equal to 47 IU/L for
resolution. If the day 16 ALT was <47 IU/L but >10 IU/L
above baseline, resolution occurred when they had 2
consecutive non-increasing ALT measurements less thanFigure 1 Subject flow and study decision points.or equal to 47 IU/L (however they could have a final ALT
more than 10 IU/L above their baseline, Figure 1). Our
secondary outcome was the proportion of subjects who
developed liver dysfunction defined by elevation of the
INR above 1.4 or serum bilirubin >2× baseline [14].
As the primary study objective was to document the
course of ALT while taking 4 gram per day of acet-
aminophen, our a-priori analysis plan was to restrict out-
come analysis to subjects who completed the full protocol
(i.e. met resolution criteria or reached study day 40). For
safety reasons, subjects who withdrew from the study
were required to have at least one measurement of ALT
off study drug.
To assure subject safety, subjects were withdrawn if
they developed drug induced liver injury as defined by
the United States Food and Drug Administration Drug-
Induced Liver Injury Premarketing Clinical Evaluation
Guidelines [14]: ALT or AST >8× the upper limit of nor-
mal (ULN); ALT or AST >5× ULN for more than 2 weeks,
ALT or AST >3× ULN and (total bilirubin >2× ULN or
INR >1.5); ALT or AST >3× ULN with the appearance of
worsening of fatigue, nausea, vomiting, right upper quad-
rant pain or tenderness, fever, rash, or eosinophilia.
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As our primary purpose was to describe the course of
ALT changes there was no obvious endpoint to use for
power calculations. Therefore, we elected to power our
study to measure the proportion of patients who did not
meet resolution criteria by study day 40. We selected
40 days as a small previous study had suggested that
many patients resolve by day 28 [5]. We determined that a
sample size of 300 completed subjects (240 acetamino-
phen: 60 placebo) was appropriate for our endpoint. This
assumes that no subjects in the acetaminophen group
would have ALT elevations that did not resolve by day 40.
Zero out of 240 subjects would result in an upper 95%
confidence limit for probability that the true incidence of
non-resolution would be less than 0.015 (less than 1.5% of
subjects would not resolve by day 40). We assumed a 15%
screen failure and a 15% dropout rate.
Randomization
Sequence generation was performed using pre-numbered
packages dispensed according to a computer generated
randomization list. We used block randomization within
the following strata: Hispanic females, Hispanic males,
non-Hispanic females, and non-Hispanic males. A sep-
arate randomized list of assignments was created for
each site based on these strata. We stratified by Hispanic
ethnicity as a previous study has suggested that the re-
sponse to acetaminophen differs between Hispanic and
non-Hispanic subjects [6].
Allocation concealment mechanism
Placebo and acetaminophen tablets were provided by
McNeil Consumer Healthcare and were identical in
appearance. Study medications were packaged into 1-week
supplies by a researcher not involved in subject manage-
ment or data collection.
Implementation
Tablets were dispensed during a study visit as a 1-week
supply and the doses for each day were provided in a
labeled packet.
Blinding
Participants, investigators and statisticians were all blinded
to the treatment groups during the main treatment period
(days 0–16). We did not assess the success of blinding.
When a subject met the criteria to stop at day 16, the
treatment group assignment was unblinded to allow
recruitment of acetaminophen-treated subjects into a
follow-up study. This occurred after completion of the
final study visit (including adverse event recording). The
physician assessing relatedness of adverse events and the
statistician performing the analysis remained blinded tosubject treatment group until the study database was
locked.Statistical methods
Demographic characteristics are presented as medians
and interquartile ranges for continuous variables and
proportions for categorical variables.
For our primary outcome analysis, we calculated a 95%
confidence interval on the proportion of subjects in the
active treatment arm with unresolved, persistent elevation
of ALT. To determine if ALT elevations were accompan-
ied by changes in liver function (secondary analysis), we
calculated a 95% confidence interval on the proportion of
subjects in the active treatment arm with elevations of
bilirubin or INR.
In a pre-planned exploratory analysis, we analyzed po-
tential associations between aminotransferase elevations
and demographic and clinical characteristics. We used
logistic regression (PROC LOGISTIC) to determine if
any of the following characteristics were associated
with our 3 secondary outcomes: age, sex, race/ethnicity
(Caucasian, Black, Hispanic, other), baseline ALT, body
mass index (BMI) and average daily alcohol consumption
(number of 14 gm servings of ethanol per day averaged
over the study duration). The 3 outcomes of interest
(defined above) were having an ALT elevation more than
1.5 times baseline, having an ALT elevation more than
10 IU/L above baseline, or meeting extension criteria at
study day 16.Results
A total of 398 subjects were screened for the study, 122
were excluded at baseline, 276 were randomized and 252
completed the study. Of the 122 excluded patients, 109
(89.3%) did not meet eligibility criteria at screening and
baseline and 13 withdrew participation prior to confirming
full eligibility (5 withdrew consent, 5 did not return for
baseline eligibility assessments, and 3 withdrew because
they could not tolerate the venipuncture). The most com-
mon reasons for screen failure (subjects could fail more
than 1 criteria) were elevated bilirubin (n = 47), elevated
INR (n = 22), elevated ALT or AST (n = 28), elevated alka-
line phosphatase (n = 4), positive viral hepatitis markers
(n = 17), history of excessive alcohol consumption (n = 9),
starting a new prescription in the preceding month (n = 4)
and history of acetaminophen ingestion in the 3 days prior
to enrollment (n = 3). The study was started on August
20, 2008 and stopped on August 16, 2011 at less than the
planned number of subjects due to a higher than expected
(31%) screen failure rate. Figure 2 is a CONSORT diagram
showing the disposition of study subjects. Placebo and
acetaminophen-treated subjects had similar baseline char-
acteristics (Table 1).
Figure 2 Consort diagram for study subjects.
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panels A-D) was unchanged from baseline at study day
4, but increased by 6 IU/L to 26 IU/L on study day 7.
The highest median ALT was observed on study day 10
(26.5 IU/L) and the median ALT decreased to 23.5 IU/L
by study day 16. Changes in AST followed a slightly
more accelerated course of elevation with the median
increasing from 21 IU/L at baseline to 27 IU/L on day 7
and decreasing back to 23 IU/L on day 16 (Figure 4
panels A-D). While there was some day-to-day variation
in subject measurements, the median ALT and AST in
the placebo group was stable throughout the study
period (Figures 3 and 4 panel E). The changes in ALT





Age (years) 32 (19.0, 64.0) 34 (18.0 to 74.0)
Male 12 (25.5%) 57 (27.8%)
Race
White 35 (74.5%) 142 (69.3%)
Hispanic 4 (8.5%) 33 (16.1%)
Black 4 (8.5%) 13 (6.3%)
Other/Mixed 4 (8.5%) 17 (8.3%)
Body Mass Index 23.8 (17.3, 48.8) 25.8 (16.5, 53.5)
Self-reported ethanol use 35 (74.5%) 167 (81.5%)
Baseline ALT 17.0 (11.0, 47.0) 19.0(9.0, 44.0)
Note: median (range) were provided for Age, BMI and Baseline ALT.(p < 0.001 repeated measure ANOVA) and the day 16
ALT was higher for the acetaminophen than the placebo
group (p < 0.001).
Of the 205 acetaminophen subjects who completed
the study, 157 (77%) did not have ALT elevations or had
transient elevations that met resolution criteria by study
day 16. Forty-eight completed subjects (23%) in the acet-
aminophen group and 1 subject (2%) in the placebo
group had ALT elevation that met criteria at day 16 to
enter the extended treatment phase. Of these 49 subjects,
the majority (n = 31) entered the extended treatment
phase because they had an ALT greater than10 IU/L above
their baseline but less than or equal to the upper reso-
lution criteria limit of 47 IU/L (including the one placebo
subject) at study day 16. One subject had an ALT less
than10 IU/L above their baseline but greater than 47 IU/L
while 17 subjects had an ALT that was both greater
than10 IU/L above their baseline and greater than 47 IU/L.
Among the 49 subjects who entered the extended treat-
ment period, 19 had a final ALT value at least 10 IU above
the baseline ALT value.
Overall, 204/205 (99.5%; 95% confidence interval 97.0
to 99.9%) acetaminophen subjects and 47/47 (100%, 95%
confidence interval 91.0 to 100%) placebo subjects met
criteria for resolution of ALT elevation by study day 40
or less while on continued study dosing regimen (acet-
aminophen or placebo). The median INR was 1.0 for the
acetaminophen group at all time points through study
day 36. The two subjects who had an INR measured at
study day 40 had a median INR of 1.1. No patient in
either group had liver dysfunction defined as elevation
Figure 3 Course of ALT for subjects administered acetaminophen (Panels A-D) and placebo (Panel E). Acetaminophen subjects were split
into 4 groups to allow better resolution of subject values.
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baseline measurement. No subject had a serum acet-
aminophen concentration greater than 40 mcg/mL (264
micromol/L).
The subject in the acetaminophen group who had an
ALT elevation that did not resolve by day 40 was monitored
for an additional three weeks after ending acetaminophen
administration. After stopping study medication, her ALT
continued to trend upward to a maximum of 105 IU/L on
study Day 63 (Figure 5) and her INR and bilirubin
remained normal. She had no symptoms of liver injury.
She was referred for evaluation by a hepatologist but did
not follow-up.Among the completed subjects, 110 (54%) of acet-
aminophen subjects and 40 placebo subjects (85%) had
a peak ALT less than 1.5 times their baseline while 95
acetaminophen subjects (46%) and 7 placebo subjects
(15%) had an ALT greater than 1.5 times their baseline.
Among the completed subjects, 115 (56%) acetaminophen
subjects and 40 (85%) placebo subjects had a peak ALT <
10 U/L above baseline while 90 acetaminophen subjects
(44%) and 7 placebo subjects (15%) had an ALT > 10 IU/L
above their baseline. For each of these outcomes a logistic
model was constructed to identify clinical or demographic
characteristics associated with the outcome in the acet-
aminophen group. The independent factors in the model
Figure 4 Course of AST for subjects administered acetaminophen (Panels A-D) and placebo (Panel E). Acetaminophen subjects were split
into 4 groups to allow better resolution of subject values.
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ethnicity, baseline ALT, alcohol user, BMI) and study
group. Age, sex, baseline ALT, alcohol use and BMI were
not related to any outcome (Table 2). Ethnicity was not
associated with entering the extended dosing outcome
group. African American subjects were at increased risk
for having an ALT increase more than 10 IU/L and there
was an overall trend that non-Caucasian subjects had
higher rates of all outcomes.
A total of 19 acetaminophen subjects and 5 placebo
subjects were withdrawn from the study after receiving at
least one dose of study medication. Reasons for withdrawal
included non-compliance (5 acetaminophen, 2 placebo),adverse event other than stopping criteria (4 acetamino-
phen, 1 placebo), day 0 ALT > 47 IU/L (4 acetaminophen)
and subject request (6 acetaminophen, 2 placebo). The
reasons subjects gave for requesting to be removed from
the trial were: inconvenience/too much time required to
participate (4 acetaminophen); no transportation (1 acet-
aminophen, 1 placebo); moved out of state (1 acetamino-
phen); and no reason given (1 placebo). No subject who
requested withdrawal had any symptoms of liver injury.
At the time of withdrawal, the median (range) ALT for
acetaminophen subjects was 19.5 IU/L (17.0, 26.0 IU/L)
for those withdrawn for non-compliance, 19 IU/L (15.0 to
28.0 IU/L) for those withdrawn after adverse events and
Figure 5 Course of ALT for the one subject who did not have
resolution of ALT elevation by study day 40. Acetaminophen
was stopped at study day 40 and ALT continued to elevate.
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drawal. Two subjects requesting withdrawal had an ALT
above the reference range. One subject had a peak ALT of
120 on study day 10 that had decreased to 67 IU/L on day
28 when the subject stopped taking acetaminophen and
withdrew. A follow-up ALT off medication on study day
30 was 54 IU/L. A second subject had an ALT of 36 on
study day 16, stopped taking study medication on study
day 18 and had an ALT of 119 IU/L on study day 21. His
ALT decreased to 46 IU/L on study day 24 while not
taking acetaminophen. For the placebo subjects request-
ing withdrawal, the ALT values at withdrawal were both
15 IU/L, for those removed for non-compliance the
ALTs at the time of withdrawal were 11 and 21 IU/L
and the subject removed for an adverse event had an
ALT of 15 IU/L at the time of withdrawal. All subjects
withdrawn had decreasing ALT documented on follow-up
testing.Table 2 Adjusted risk for secondary outcomes for subjects tre
Extended dosing
Variable Odds ratio 95%
Confidence interval
Odds
Female (vs Male) 1.47 0.64 to 3.73 1.0
Race
Caucasian 1.0 Ref 1.0
Black 1.71 0.47 to 6.26 3.5
Hispanic 1.86 0.79 to 4.40 1.4
Other 1.85 0.58 to 5.91 1.4
Age (per yr) 1.01 0.98 to 1.04 1.0
Baseline ALT (Per IU/L) 1.03 0.98 to 1.08 1.0
BMI 0.98 0.93 to 1.04 0.9
No ethanol use 1.81 0.81 to 4.1 0.9Self-reported medication compliance, as measured by
the diary was similar for both groups. The median (inter-
quartile range) percent of days where subjects took all 4
doses was 100% (86.7 to 100%) for the acetaminophen
group and 86.5% (81.1 to 100%) for the placebo group.
Adverse events
The overall proportion of subjects reporting any adverse
event was 62.3%; 65.6% of the acetaminophen subjects
and 48.1% of the placebo subjects. The characteristics of
the adverse events are listed in the online supplement
(Additional file 1: Table S3.pdf Adverse Events). The most
commonly reported adverse events were gastrointestinal.
The majority of adverse events were rated as unrelated or
possibly related to study drug. Nausea was the most
frequent adverse event rated as probably related or related
to study drug. No serious adverse events were reported.
The proportion of acetaminophen-treated subjects suffer-
ing adverse events was similar for those who had an ALT
elevation >10 IU/L: nausea 15/90 (16.7%) in those with
elevation and 19/115 (16.5%) in those without; vomiting
2/90 (2.2%) in those with elevation and 2/115 (1.7%) in
those without and abdominal pain 6/90 (6.7%) in those
with elevation and 6/115 (5.2%) in those without.
Discussion
We found that ingestion of 4 grams per day of acet-
aminophen for a minimum of 16 days caused no signifi-
cant change in ALT in approximately half of subjects,
and a transient elevation that resolved by day 16 in
approximately a quarter of patients. The remaining quar-
ter of patients had modest ALT elevations that resolved
when administration was continued over the next 24 days
in all but one subject. The maximum observed ALT was
191 IU/L. No patient experienced drug-induced liver
injury as defined by a Food and Drug Administrationated with 4 g/acetaminiophen/day





3 0.53 to 2.03 1.21 0.61 to 2.39
Ref 1.0 Ref
6 1.02 to 12.45 1.80 0.54 to 5.99
5 0.66 to 3.2 1.67 0.75 to 3.69
0 0.50 to 3.96 1.81 0.63 to 5.24
2 0.99 to 1.04 1.02 1.00 to 1.05
1 0.97 to 1.05 0.96 0.92 to1.00
8 0.93 to 1.03 0.99 0.94 to 1.04
0 0.42 to 1.92 0.89 0.42 to 1.88
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while their aminotransferase activity was elevated. The
proportion of acetaminophen subjects experiencing
gastrointestinal symptoms was similar for those with
and without ALT elevations.
Only one patient’s ALT elevation failed to resolve during
continued administration of acetaminophen. The subject
had no changes in INR or bilirubin, suggesting there was
no liver dysfunction. Furthermore, this subject’s amino-
transferase elevation continued to increase for 3 weeks
after acetaminophen was stopped. As with any single case
observation, it is not possible to determine causality, even
within a clinical trial. However, this pattern of slowly
progressive ALT elevation weeks after exposure is not
consistent with acetaminophen-induced liver injury [15]
and data from other randomized trials suggests that
ALT elevations suspected to be related to acetamino-
phen resolve once acetaminophen is stopped [2,4,6,8].
This pattern of ALT increase suggests an alternative
cause of aminotransferase elevation such as infection
[16] or a change in diet [17]. Unfortunately, the subject
declined a comprehensive hepatology evaluation (as
planned in the study protocol). This limited our ability
to identify potential causes for her ALT elevation.
As noted in previous studies [3,6], we found no associ-
ation between aminotransferase elevation (using either
of two definitions) and age or gender. While a previous
study suggested an increased risk of elevation for Hispanic
subjects [6], our study found no difference between
Hispanic and Caucasian subjects. We also found no as-
sociation between ethanol use and aminotransferase
elevation. While there have been no previous trials that
directly compare the effect of acetaminophen between
drinkers and non-drinkers, separate studies have reported
the effect sizes in these two groups. A study of moderate
ethanol users administered 4 g/day of acetaminophen for
10 days reported a median ALT elevation of 8 IU/L [3]
while a similar study in non-drinkers (using a more fre-
quent sampling pattern) reported a median ALT elevation
of 15 IU/L [4]. The current study suggests that the amino-
transferase elevations do not differ between drinkers and
non-drinkers and suggests that the differences in the pre-
vious trials are due to different sampling methods.
The degree of aminotransferase elevation caused by
repeated therapeutic doses of acetaminophen has var-
ied greatly among prior studies. Studies of ambulatory
subjects have consistently reported that the highest
observed elevation is less than 3 times the upper limit
of normal [3-5,18], while studies of subjects confined
to a clinical research facility reported elevations more than
8 times the upper limit of normal [2,6]. While the exact
reason for these differences is not clear, there is meta-
analytic evidence that subjects on a clinical research unit
may increase their aminotransferase activity independentof treatment [19]. This meta-analysis compared the change
in ALT for the placebo groups in studies where subjects
were admitted to a clinical research unit to the change in
ALT for the placebo group in studies where subjects were
ambulatory. They noted that almost 10% of placebo treated
patients on a clinical research unit had an increase in ALT
that was at least 50% of the reference range width, while
no outpatient subjects had elevations of this degree. It is
possible that the marked increases observed in the acet-
aminophen group within studies using a clinical research
unit are due to a potentiation of the acetaminophen effect
by confinement. The clinical implications of an interaction
between hospitalization and suggested acetaminophen-
induced ALT elevations warrant further investigation. In
a small observational study of inpatients (surgical and
medical patients), acetaminophen users had an increased
risk of developing an elevation of ALT compared to
non-acetaminophen users [20]. While the elevations
observed in this study were minimal, it is possible that
acetaminophen-induced ALT elevations could progress
to clinical liver injury if potentiated by other factors
such as CYP 2E1 induction, malnutrition or oxidative
stress. However, analysis of prospective trials that
treated adult or pediatric patients with the therapeutic
doses for a variety of medical conditions found no
cases of acute liver failure [1,21].
Acetaminophen is frequently used in both combination
and single ingredient products for prolonged periods. The
rarity of alleged cases of hepatic injury from therapeutic
doses is strong evidence that these doses are safe even
though ALT elevations occur. Until recently, ALT eleva-
tions alone during pre-clinical studies were considered a
signal that would often lead a company to stop seeking ap-
proval for candidate drugs. However, the recent guidelines
emphasize the importance of changes in hepatic function
(INR and bilirubin) in addition to elevations of amino-
transferase activity [22]. These guidelines recognize that a
large number of medications cause self-limited ALT eleva-
tions that are not a precursor to clinical liver injury and
are not an indication to stop therapy.
Other medications that cause self-limited aminotrans-
ferase elevations include amiodarone, tacrine, heparin,
isoniazid and the statins [23-27]. While liver failure has
rarely been linked to isoniazid and amiodarone, there
are no cases definitively caused by tacrine or heparin
and the cases linked to the statins have been questioned
[28]. These observations have led some to postulate that
these transient elevations of the serum transaminase re-
flect hepatic adaptation [22]. While the mechanism is not
clear hepatic adaptation may also occur with repeated
acetaminophen dosing.
Our study population was limited to healthy volunteers,
so it is possible that subjects with underlying liver disease
or other medical conditions may have a different course of
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Our internal validity is limited by the loss of several
subjects prior to completing the protocol. It is possible
that these subjects would not have resolved prior to
completing the study. This would lead us to underestimate
the proportion of subjects who did not resolve. We were
also limited by not reaching our planned sample size, and
this decreased our overall study power. Our study is also
limited by the use of two biomarkers (ALT and AST). It is
possible that other biomarkers may produce different pat-
terns of change.
Conclusions
It is now clear that therapeutic doses of acetaminophen
when administered for consecutive days may cause mild to
moderate ALT elevations. These aminotransferase eleva-
tions are relatively common, usually less than 10 IU/L, not
accompanied by liver dysfunction and resolve even when
acetaminophen therapy is continued.
Additional file
Additional file 1: Table S3. Adverse Events by class for all randomized
subjects. Subjects were treated with acetaminophen (4 g/day) or placebo).
Abbreviation
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; BMI: Body
mass index; CI: Confidence interval; INR: International Normalized Ratiol;
ULN: Upper limit of normal.
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